One E-Commerce Corp (ISLT) 0.1800 $ISLT
Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that its collaborators at the Yale University School of Medicine have published key data highlighting the efficacy of Islet's novel diabetes diagnostic in Endocrinology, the journal of the Endocrine Society. The study demonstrated improved detection of beta-cell loss, a key biomarker of diabetes progression, using a novel technology called droplet digital PCR (ddPCR).
Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
PR Newswire - Mon Jun 23, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The poster was presented this past Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
PR Newswire - Wed Jun 18, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
PR Newswire - Mon Jun 16, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, presented final results from its two Phase 2b clinical studies evaluating remogliflozin etabonate (a prodrug of remogliflozin, the active inhibitor) at the 74th American Diabetes Association (ADA) Annual Scientific Sessions, showing that the differentiated sodium glucose co-transporter 2 (SGLT2) inhibitor demonstrated a potential best-in-class safety and efficacy profile, when dosed once-daily or twice-daily, respectively. Positive Phase 1 results were also presented for the company's novel once-daily biphasic formulation of remogliflozin etabonate, which achieved targeted pharmacokinetic and pharmacodynamic profiles, successfully combining the best-in-class properties of previous formulations.
Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
PR Newswire - Thu Jun 12, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.
Islet Sciences, Inc. Appoints Steven Delmar as Chief Financial Officer
PR Newswire - Thu May 29, 6:57AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the diagnosis and treatment of metabolic disease, announced today the appointment of Steven Delmar, CPA, as Chief Financial Officer. Mr. Delmar brings more than 35 years of financial and operational executive leadership experience to the company, serving most recently as Director of Business Operations at Computer Sciences Corporation (CSC). Mr. Delmar's appointment was effective May 22, 2014, and he is based in Islet Sciences' North Carolina headquarters.
Islet Sciences to Host Conference Call to Discuss Acquisition of BHV Pharma
Marketwire - Mon Mar 17, 8:30AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced that on Monday, March 17, 2014, the Company will host a conference call to discuss the announced acquisition of BHV Pharma. The call is scheduled to take place at 4:15 p.m. ET.
Islet Sciences appoints Dr. Michael Luther to board
M2 - Mon Mar 17, 7:55AM CDT
US-based biopharmaceutical company Islet Sciences (OTCQB:ISLT) revealed on Friday the addition of Dr. Michael Luther to its board of directors.
Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors
Marketwire - Fri Mar 14, 8:10AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced the appointment of Dr. Michael Luther, Senior Vice President of Discovery and Development at Albany Molecular Research, Inc. to Islet's Board of Directors.
Islet Sciences to buy BHV Pharma, including Phase two SGLT2 inhibitor remogliflozin etabonate for Type 2 diabetes and NASH
M2 - Fri Mar 14, 4:10AM CDT
Biopharmaceutical company Islet Sciences (OTCBB:ISLT) (OTCQB:ISLT) said on Thursday that it has entered into a binding letter of intent to acquire Brighthaven Ventures /BHV Pharma (BHV), including the remogliflozin programme.
Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH
Marketwire - Thu Mar 13, 8:15AM CDT
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that it has signed a binding letter of intent to acquire Brighthaven Ventures, LLC d/b/a BHV Pharma ("BHV"
. BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" . Remogliflozin is currently in phase 2 clinical development.
CORWIL Technology Corporation Completes Asset Purchase Of VIKO Test Labs
PR Newswire - Mon Mar 10, 10:01PM CDT
CORWIL Technology Corporation ("CORWIL" has announced the asset purchase of VIKO Test Labs, a division of Infiniti Solutions. The addition of electrical, environmental, and mechanical test services enhances CORWIL's market position as a true OSAT (Outsourced Semiconductor Assembly & Test) leader, joining an exclusive list of domestic providers with both assembly and test operations located in the United States.
Islet Sciences Inc names Dr Eric Barnett to board
M2 - Tue Jan 07, 5:47AM CST
Biopharmaceutical company Islet Sciences Inc (OTCBB:ISLT) (OTCQB:ISLT) reported on Monday the election of Dr Eric Barnett to its board of directors.
Dr. Eric Barnett Joins Islet Sciences, Inc. Board of Directors
Marketwire - Mon Jan 06, 11:11AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals LLC, was elected to the Islet Sciences Board of Directors.
Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Marketwire - Thu Dec 12, 7:01AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)
Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."
Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.
Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that its collaborators at the Yale University School of Medicine have published key data highlighting the efficacy of Islet's novel diabetes diagnostic in Endocrinology, the journal of the Endocrine Society. The study demonstrated improved detection of beta-cell loss, a key biomarker of diabetes progression, using a novel technology called droplet digital PCR (ddPCR).
Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
PR Newswire - Mon Jun 23, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The poster was presented this past Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
PR Newswire - Wed Jun 18, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.
Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
PR Newswire - Mon Jun 16, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, presented final results from its two Phase 2b clinical studies evaluating remogliflozin etabonate (a prodrug of remogliflozin, the active inhibitor) at the 74th American Diabetes Association (ADA) Annual Scientific Sessions, showing that the differentiated sodium glucose co-transporter 2 (SGLT2) inhibitor demonstrated a potential best-in-class safety and efficacy profile, when dosed once-daily or twice-daily, respectively. Positive Phase 1 results were also presented for the company's novel once-daily biphasic formulation of remogliflozin etabonate, which achieved targeted pharmacokinetic and pharmacodynamic profiles, successfully combining the best-in-class properties of previous formulations.
Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
PR Newswire - Thu Jun 12, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.
Islet Sciences, Inc. Appoints Steven Delmar as Chief Financial Officer
PR Newswire - Thu May 29, 6:57AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the diagnosis and treatment of metabolic disease, announced today the appointment of Steven Delmar, CPA, as Chief Financial Officer. Mr. Delmar brings more than 35 years of financial and operational executive leadership experience to the company, serving most recently as Director of Business Operations at Computer Sciences Corporation (CSC). Mr. Delmar's appointment was effective May 22, 2014, and he is based in Islet Sciences' North Carolina headquarters.
Islet Sciences to Host Conference Call to Discuss Acquisition of BHV Pharma
Marketwire - Mon Mar 17, 8:30AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced that on Monday, March 17, 2014, the Company will host a conference call to discuss the announced acquisition of BHV Pharma. The call is scheduled to take place at 4:15 p.m. ET.
Islet Sciences appoints Dr. Michael Luther to board
M2 - Mon Mar 17, 7:55AM CDT
US-based biopharmaceutical company Islet Sciences (OTCQB:ISLT) revealed on Friday the addition of Dr. Michael Luther to its board of directors.
Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors
Marketwire - Fri Mar 14, 8:10AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced the appointment of Dr. Michael Luther, Senior Vice President of Discovery and Development at Albany Molecular Research, Inc. to Islet's Board of Directors.
Islet Sciences to buy BHV Pharma, including Phase two SGLT2 inhibitor remogliflozin etabonate for Type 2 diabetes and NASH
M2 - Fri Mar 14, 4:10AM CDT
Biopharmaceutical company Islet Sciences (OTCBB:ISLT) (OTCQB:ISLT) said on Thursday that it has entered into a binding letter of intent to acquire Brighthaven Ventures /BHV Pharma (BHV), including the remogliflozin programme.
Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH
Marketwire - Thu Mar 13, 8:15AM CDT
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that it has signed a binding letter of intent to acquire Brighthaven Ventures, LLC d/b/a BHV Pharma ("BHV"
. BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" . Remogliflozin is currently in phase 2 clinical development. CORWIL Technology Corporation Completes Asset Purchase Of VIKO Test Labs
PR Newswire - Mon Mar 10, 10:01PM CDT
CORWIL Technology Corporation ("CORWIL"
has announced the asset purchase of VIKO Test Labs, a division of Infiniti Solutions. The addition of electrical, environmental, and mechanical test services enhances CORWIL's market position as a true OSAT (Outsourced Semiconductor Assembly & Test) leader, joining an exclusive list of domestic providers with both assembly and test operations located in the United States. Islet Sciences Inc names Dr Eric Barnett to board
M2 - Tue Jan 07, 5:47AM CST
Biopharmaceutical company Islet Sciences Inc (OTCBB:ISLT) (OTCQB:ISLT) reported on Monday the election of Dr Eric Barnett to its board of directors.
Dr. Eric Barnett Joins Islet Sciences, Inc. Board of Directors
Marketwire - Mon Jan 06, 11:11AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals LLC, was elected to the Islet Sciences Board of Directors.
Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Marketwire - Thu Dec 12, 7:01AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)
Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."
Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.
